Stephen Ezell, said calls to use march-in rights to control drug prices could allow a government entity to retroactively commandeer innovations that private-sector enterprises invested hundreds of millions, if not billions, of dollars to create. “That threat would significantly reduce the pace of biopharmaceutical innovation,” he told Bloomberg Law.
